Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
Elevai Labs, Inc. (ELAB)
Company Research
Source: GlobeNewswire
NEWPORT BEACH, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skin care, is proud to announce the launch of its online E-commerce portal. The new E-commerce portal serves as a business-to-business (B2B) extension of the Company’s existing B2B relationship with physician dispensed providers currently offering ELEVAI products in the $19.7 billion global industry1. Through the Company’s online platform, retail customers can now select a physician provider to start their personalized skin care journey and enjoy the ease and convenience of online re-ordering. Benefits to ELEVAI with the launch of the ecommerce portal include: Physicians can now offer ELEVAI’s professional-grade products, having them delivered directly to patients. These same customers have the option to reorder directly from the ELEVAI E-commerce portal, allowing ELEVAI to share the economic benefits with physicians;Potential
Show less
Read more
Impact Snapshot
Event Time:
ELAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELAB alerts
High impacting Elevai Labs, Inc. news events
Weekly update
A roundup of the hottest topics
ELAB
News
- Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity [Yahoo! Finance]Yahoo! Finance
- Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of ObesityGlobeNewswire
- Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare [Yahoo! Finance]Yahoo! Finance
- Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome SkincareGlobeNewswire
ELAB
Sec Filings
- 5/9/24 - Form 8-K
- 5/2/24 - Form 8-K
- 3/29/24 - Form 10-K
- ELAB's page on the SEC website